


PFIZER INC. NYSE:PFE

RECENT PRICE **35.01** P/E RATIO **19.1** (Trailing: 10.0 Median: 18.0) RELATIVE P/E RATIO **1.04** DIV'D YLD **3.9%** **VALUE LINE**



2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	© VALUE LINE PUB. LLC	21-23
5.25	5.92	7.03	6.97	6.79	7.16	7.16	6.20	8.46	8.90	8.11	8.06	7.89	7.91	8.70	8.79	9.25	9.65	Sales per sh	10.90
1.72	2.21	2.84	2.80	2.85	3.03	1.94	1.66	2.09	2.34	2.35	2.77	2.32	1.96	2.13	2.82	3.00	3.30	"Cash Flow" per sh	3.85
1.53	1.75	2.12	2.02	2.06	2.20	1.18	1.23	1.03	1.11	1.26	1.65	1.41	1.11	1.17	1.73	2.00	2.30	Earnings per sh A G	2.90
.52	.60	.68	.76	.96	1.16	1.28	.80	.72	.80	.88	.96	1.04	1.12	1.20	1.28	1.36	1.44	Div'ds Decl'd per sh B	1.68
.29	.35	.35	.29	.29	.28	.25	.15	.19	.22	.18	.19	.19	.23	.30	.33	.35	.35	Cap'l Spending per sh	.35
3.24	8.53	9.10	8.88	9.98	9.60	8.52	11.15	10.95	10.84	11.16	11.92	11.33	10.48	9.81	11.93	12.20	12.60	Book Value per sh C	14.00
6162.0	7629.0	7473.0	7361.0	7124.0	6761.0	6746.0	8070.0	8012.0	7575.0	7276.0	6399.0	6291.0	6175.0	6070.0	5979.0	5900.0	5800.0	Common Shs Outst'g D	5500.0
22.8	18.2	15.6	12.7	12.5	11.5	16.4	12.8	16.3	17.6	18.4	17.6	21.5	30.3	28.1	19.7	Bold figures are Value Line estimates		Avg Ann'l P/E Ratio	18.0
1.25	1.04	.82	.68	.67	.61	.99	.85	1.04	1.10	1.17	.99	1.13	1.53	1.47	.96			Relative P/E Ratio	1.00
1.5%	1.9%	2.1%	3.0%	3.7%	4.6%	6.6%	5.1%	4.3%	4.1%	3.8%	3.3%	3.4%	3.3%	3.7%	3.8%			Avg Ann'l Div'd Yield	3.2%

CAPITAL STRUCTURE as of 12/31/17		2015	2016	12/31/17	Leases, Uncapitalized		Pension Assets-12/17		Common Stock		MARKET CAP: \$209 billion (Large Cap)		CURRENT POSITION (SMILL.)		ANNUAL RATES		QUARTERLY SALES (\$ mill.)		EARNINGS PER SHARE A		QUARTERLY DIVIDENDS PAID B	
Total Debt \$43491 mill. Due in 5 Yrs \$14666 mill.		48296	50009	67809	Annual rentals \$209.0 mill.		\$23.1 bill. Oblig. \$28.8 bill.		5,952,864,751 shs. as of 2/20/18		\$209 billion (Large Cap)		Cash Assets 23290		Past 10 Yrs. 1.5%		Mar.31 Jun.30 Sep.30 Dec.31		.38 .42 .34 d.03		.26 .26 .26 .26	
LT Debt \$33538 mill. LT Interest \$1270 mill. (32% of Cap'l)		45.9%	46.2%	45.5%									Receivables 8176		Past 5 Yrs. 1.0%				.49 .33 .21 .13		.28 .28 .28 .28	
		5090.0	4757.0	8487.0									Inventory (LIFO) 7513		Est'd '15-'17 to '21-'17 4.5%				.51 .51 .47 .23		.30 .30 .30 .30	
		8026.0	8621.0	8266.0									Other 4825		1.0%				.55 .55 .50 .40		.32 .32 .32 .32	
		17.0%	20.3%	11.9%									Current Assets 43804						.65 .65 .55 .45		.34	
		16.6%	17.2%	12.2%									Accts Payable 3620									
		16067	24445	31859									Debt Due 10160									
		7963.0	43193	38410									Other 15619									
		57556	90014	87813									Current Liab. 29399									
		12.6%	6.8%	7.1%																		
		13.9%	9.6%	9.4%																		
		NMF	3.4%	2.5%																		
		NMF	64%	74%																		

BUSINESS: Pfizer Inc. is a research-based, global biopharmaceutical company engaging in the discovery, development, manufacture, and sale of healthcare products. Portfolio includes medicines, vaccines, and various consumer healthcare products. Manages commercial operations through two segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH), which was previously known as Established Products. Highest-grossing products '17: *Plevnar*, *Lyrica*, *Ibrance*, *Eliquis*, *Enbrel*, *Lipitor*, and *Xeljanz*. Has 90,200 employees. Dirs/Off. own less than 1% of common stock; Black-Rock, 7.6%; Vanguard, 7.3%; State Street, 5.3% (3/18 proxy). Chairman/CEO: Ian C. Read. Inc.: Del. Addr.: 235 East 42nd St., New York, NY 10017. Tel.: 212-733-2323. Internet: www.pfizer.com

Pfizer is well positioned for growth in 2018. The drugmaker's fourth-quarter results beat consensus expectations, driven by stronger demand in several core franchises (*Plevnar*, *Eliquis* and *Xeljanz*) and a benefit from tax reform. This helped to mitigate some softness in top oncology asset *Ibrance*, where sales were a bit light due to a price cut in Europe. While the core lineup is expected to face some pressure in the year ahead, further development of newer assets and a more favorable tax code should more than offset the impact. For full-year 2018, management is targeting adjusted earnings of \$2.90-\$3.00 a share on sales of \$53.5 billion-\$55.5 billion, representing annual growth of 11% and 4%, respectively, at the midpoints. The guidance includes the contribution from its Consumer Healthcare business. **We are likely to see some erosion in several core products this year.** The top-grossing *Plevnar* vaccine franchise rebounded nicely in the back half of 2017, but much of the gain was driven internationally and a saturated U.S. market (Q4 sales -7%) remains a key overhang. The company's #2 seller *Lyrica* lost patent protection in Europe and could soon be facing increased competition in the U.S., though management is optimistic it can avoid this scenario until mid-2019. Continued declines in *Enbrel* and *Viagra* are likely to take a toll, as well. Given that these four products combined account for roughly a quarter of Pfizer's total revenue, further development of the new product cycle and pipeline will be imperative. We also wouldn't be surprised to see some M&A. ***Ibrance*, *Xeljanz*, and *Eliquis* should lead the way.** Despite the Q4 miss, we look for *Ibrance* to account for the majority of revenue growth in 2018. Uptake trends remain strong in the U.S. (Q4 sales +27%), particularly in the breast cancer setting, and the price cut in Europe largely overshadowed continued healthy volumes in the region (+20% quarter to quarter). **The stock is ranked 2 (Above Average) for Timeliness.** Based on our system, PFE shares represent one of the more attractive year-ahead growth plays in the large pharma space. An above-average dividend yield and favorable risk profile further bolster near-term investment appeal. *Michael Ratty* April 6, 2018

(A) Diluted earnings (GAAP). May not sum due to change in share count. Excludes one-time gain of \$1.79 a share in Q4, 2017. Next earnings report due early May. (B) Dividends paid in early Mar., Jun, Sep., Dec. (C) Includes intangibles. In '17: \$104.4 bill., \$17.46/sh. (D) In millions. (E) Pharmacia acqd. 4/03, included from 2nd qtr. (F) Wyeth acqd. 10/09, included from 4th qtr. (G) Switched to GAAP earnings from adjusted in 2008.	Company's Financial Strength	A++
	Stock's Price Stability	95
	Price Growth Persistence	65
	Earnings Predictability	55